72
Participants
Start Date
July 31, 2006
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
ATI-2042
no intervention
ATI-2042 200 mg
To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
ARYx Investigational Site, Buffalo
ARYx Investigational Site, Hershey
ARYx Investigational Site, Wynnewood
ARYx Investigational Site, Towson
ARYx Investigational Site, Newport News
ARYx Investigational Site, Charleston
ARYx Investigational Site, Charleston
ARYx Investigational Site, Marietta
ARYx Investigational Site, Atlanta
ARYx Investigational Site, Jacksonville Beach
ARYx Investigational Site, Hollywood
ARYx Investigational Site, Nashville
ARYx Investigational Site, Saginaw
ARYx Investigational Site, Minneapolis
ARYx Investigational Site, Chicago
ARYx Investigational Site, St Louis
ARYx Investigational Site, Lincoln
ARYx Investigational Site, Houston
ARYx Investigational Site, Austin
ARYx Investigational Site, Aurora
ARYx Investigational Site, Scottsdale
ARYx Investigational Site, Phoenix
ARYx Investigational Site, Tucson
ARYx Investigational Site, Albuquerque
ARYx Investigational Site, Larkspur
ARYx Investigational Site, Warren Township
ARYx Investigational Site, Burlington
ARYx Investigational Site, Edmonton
ARYx Investigational Site, Edmonton
ARYx Investigational Site, Campbell River
ARYx Investigational Site, Vancouver
ARYx Investigational Site, Victoria
ARYx Investigational Site, London
ARYx Investigational Site, Niagara Falls
ARYx Investigational Site, Ottawa
ARYx Investigational Site, Montreal
ARYx Investigational Site, Montreal
ARYx Investigational Sites, Montreal
ARYx Investigational Site, Sherbrooke
ARYx Investigational Site, Terrebonne
Lead Sponsor
ARYx Therapeutics
INDUSTRY